Naloxone nasal spray in Norway Thomas Clausen Professor (Dr. med) 5. November 2015.

Slides:



Advertisements
Similar presentations
Daliah Heller, PhD, MPH Assistant Commissioner
Advertisements

Sharon Stancliff, MD Caroline Rath, PA-C Harm Reduction Coalition New York, NY USA.
Cindy Powers Magrini, PharmD, BCPS
OVERDOSE PREVENTION PROGRAM Shawn Woods Manager, CDC Department Representing: CDC Department CDIP Department.
MDM Harm Reduction (needle exchange) program in Kabul-Afghanistan.
Project Coordinator Overdose Prevention Project, Prevention Point Pittsburgh Alice Bell, LCSW.
Opioid Safety Phillip Coffin, MD, MIA Director of Substance Use Research San Francisco Dept. of Public Health Assistant Clinical Professor University of.
Heroin overdose: Myths, facts and intervention
HIV/AIDS Asia Regional Project (HAARP) Training Program for Police Effective Strategies for reducing the spread of HIV/AIDS among and from Injecting Drug.
The Take Home Naloxone Program in British Columbia, Canada Erin Gibson, Despina Tzemis, Jane Buxton BC Centre for Disease Control Harm Reduction Program.
Overdose deaths from street heroin and prescribed methadone: analysis and prevention options Professor John Strang National Addiction Centre, London, UK.
HIV and drug prevention in Estonia Harm reduction services
Strategies for Incorporating OD Prevention Into Your Work Eliza Wheeler Drug Overdose Prevention & Education (DOPE) Project Harm Reduction Coalition
Implementation in Ohio’s Regional Psychiatric Hospitals.
Injection drug users’ knowledge about overdose prevention and take home Naloxone in Ukraine. ICF 'International HIV/AIDS Alliance in Ukraine Liudmyla Shulga.
Jennifer Hillebrand, „Rehabilitation of Drug Addicted Persons: Experience of Lithuania and European Countries”, 18 October 2007 Improving drug treatment.
Naloxone (Narcan) A true opioid overdose antidote.
Recommendations on the Management of Opioid Overdose Ruth Birgin.
Annual report 2010: the state of the drugs problem in Europe.
SOHO RAPID ACCESS CLINIC. AIMS: n To provide a client focussed, low threshold flexible prescribing service. n To offer an easily accessible assessment.
Washington D.C., USA, July 2012www.aids2012.org Human rights as a key component of harm reduction strategy targeting people using drugs in Morocco.
Quaboag Hills Community Coalition Substance Use Task Force October 20, 2014 Overview of the Strategic Prevention Framework (SPF) “Road Map” What are Evidence-Based.
Overdose: A major preventable cause of death in Eastern Europe and Central Asia Shona Schonning.
Take-home naloxone from October 2015
Allegheny County Overdose Prevention Coalition
Grampian Naloxone Programme
Trends in Opioid Use and Overdose in BC: Making the case for greater availability of Take Home Naloxone programs Ashraf Amlani Harm Reduction Epidemiologist.
School of Public Health and Community Medicine How policies and repressive law- enforcement fuel the HIV epidemic among people who inject drugs Professor.
1 Evaluation of the Take Home Naloxone (THN) Project Trevor Bennett Katy Holloway.
1 December 8, 2015 Crista M. Taylor, LCSW-C Director, Information, Planning and Development Adrienne Breidenstine, MSW Director of Opioid Overdose Prevention.
The Heroin Epidemic in rural Maryland Rural Health Learning Collaboration Sept. 28, 2015 James A. Cockey, MD, FACP Deputy Health Officer.
Heroin Rising: the Resurgence of Heroin and Opiate Abuse
Harm Reduction Team Maureen Woods Team Leader. Service Delivery Aims Develop harm reduction initiatives in partnership with other agencies to reduce the.
SARAH M. BAGLEY, MD ASSISTANT PROFESSOR OF MEDICINE AND PEDIATRICS BOSTON UNIVERSITY SCHOOL OF MEDICINE AMERSA ANNUAL CONFERENCE NOVEMBER 5, 2015 Overdose.
The Impact on Caregivers of Young Adult Opioid Use Sarah Bagley MD Addiction Medicine Fellow Clinical Addiction Research and Education Unit Boston University.
Factors associated with concurrent Heroin use among patients on Methadone maintenance treatment in Vietnam from 2008 to 2013 Hoang Nam Thai MD, MPH – CDC/DGHT.
BEST PRACTICE PORTAL BEST PRACTICE PORTAL project presentation to the Scientific Committee Ferri et al Lisbon, 16th July 2010.
Naloxone: Prescribing and Dispensing
Naloxone for Entities & Laysavers Aaron Kochar, J.D.
Opiate overdose. Opiate overdose (ONS, 2012) The most common acute cause of drug-related death is opiate overdose. Over half – 596 (57 per cent) - of.
Bystander Naloxone Training Saves Lives. Death rates are spiraling out of control--for both prescription opioids and heroin! Graphic: Nytimes.com.
Overdose Prevention Pilot Project Cross Systems Collaboration. Naloxone Distribution In cooperation with LA Community Health Project June 4, 2014, VCBH,
Private and confidential Community Pharmacy Future Four-or-more medicines support service Update on progress and next steps Approved18 th June 2012 This.
Walking a Thin “Wire”: The Attitudes and Principles of Harm Reduction Niladri Das, MD UPMC St. Margaret Family Medicine Residency Daniel Dejoseph,MD Drexel.
or you can use Text Voting by texting ”nmpha” to 22333
State Targeted Response to Opioid Crisis
10th Annual Susan Li Conference
Enhanced Pharmacy Provision in Edinburgh:
MacColl Center for Health Care Innovation
APHA 135th Annual Meeting and Expo November 3-7, 2007 Washington, DC
An overdose Reduction PlaN
Provincial Fire Department program
Pharmacokinetics of a novel nasal spray in development in Europe
Experiences from a national overdose prevention strategy: Nasal naloxone distribution and lessons learned Philipp Lobmaier, MD, PhD Norwegian Centre.
Steve Alsum The Grand Rapids Red Project
A State Targeted Response to the Opioid Crisis:
Lisbon Addictions 2017 Liv Flesland, Consultant
New non-injectable naloxone products: Global overview
First Responder Naloxone Grant Webinar
Mortality during Opioid Maintenance Treatment in Norway in the years 2014 and 2015 Anne Bech1, Thomas Clausen2, Helge Waal2,3, Ivar Skeie4,2 Norwegian.
Head of Research centre
Needle exchange program
Opioid-related harms and responses
GACD Annual Scientific Meeting
Naloxone in North Carolina
Copyright Notice This presentation is copyrighted by the Psychopharmacology Institute. Subscribers can download it and use it for professional use. The.
Strategic Initiatives to Address Opioid Overdose & Addiction
Human Dignity and Harm Reduction
SAVE a LIFE YOU CAN WITH a SPRAY
March 8, 2006 New ACIP Hepatitis B Recommendations
Presentation transcript:

Naloxone nasal spray in Norway Thomas Clausen Professor (Dr. med) 5. November 2015

Conflicts of interest None  Thomas Clausen is a full-time employee at the Norwegian Centre for Addiction Research, University of Oslo, Norway

Norway Population: 5 mill +/ opioid drug users 90% inject Heroin & polydrug in OMT  Universal health care system Free access to treatment

Background Norway has high rates and numbers of fatal overdoses (ODs) OMT coverage +/- 60% Increasing evidence: Take-home-Naloxone may reduce fatal ODs

National Strategy  Minister of Health; launched national overdose prevention strategy (2014) 5-year overdose prevention strategy – 0-vision for ODs in the long-term – Includes multiple sub-strategies as well as funding Nasal naloxone distribution Accompanied by research/evaluation funds

Naloxone coverage per 100KOpioid overdose death rate 27% reduction 46% reduction Fatal opioid OD rates by nasal naloxone introduction rates Walley et al. BMJ 2013; 346: f174.

Prior to distribution No available nasal naloxone in Norway  NOMA approved Nasal naloxone (June 2014) – Based on EU-MA medication (injectable, for peer-admin.)  New route of administration  2mg/2ml – 5 dose - Prefilled syringe + Nasal adapter (MAD300) > No needles – No individual prescription

Nasal application Considerations Increasing clinical/epidemiological evidence from US Lower risk for 3.party injury Expected lower barrier to use No history of failure from clinical practice Perceived overall positive Benefit/Harm ratio  Above supported rapid implementation  Lack of formal PK-data – Project (partial) implementation

Nasal naloxone: Project-structure Implementation in 2 largest cities (1/3 of ODs) 2-year pilot period Formal evaluation of project Is distribution feasible and does it work?  Recommendations for future, based on local and international evidence

Overdose Prevention Training A public health approach  Training existing staff with 2-hour sessions – 500+ staff  Multiple sites- Housing facilities Drop-in day centres Services “on-wheels” Police Family members/Relatives Prisons Detox OMT Rescue breathing Call ambulance Use Naloxone

Status October naloxone kits distributed 400+ returns for refills – 60% used in OD situation – Of 215 feedback forms (July 15): – 1 died, and 11 unknown outcome  Aim to distribute at least 100 kits/ in the two cities (annual ODs +/- 80)  Aim; minimum 900 sprays (within one year)

Success factors Governmental support & funding Part of national strategy NOMA approved nasal medication Local pharma company No individual prescriptions Relying on existing healthcare facilities Involvement of user-groups

…and obstacles Getting general approval for a new route (nasal) of administration of Naloxone New kits to come, seem to be one-dose only with relatively high concentration Cost; price per kit; 50$

Feedback from client [Upon her 3 rd refill] “It’s worked every time. I see he’s blue, and then within a few minutes he’s up standing! Should have had it sooner. I’ve seen too many of these [overdoses].” - Client, drop-in center Bergen

Norwegian nasal naloxone 5 doses of 0,4mg Naloxone

Naloxone Nasal Spray in Norway Contact